WebMar 31, 2024 · 16.76% of Delcath Systems stock is owned by insiders. Learn more on DCTH's insider holdings. Which Delcath Systems insiders have been buying company stock? The following insiders have purchased DCTH shares in the last 24 months: Gerard J Michel ($919,830.86), John Purpura ($85,843.00), Rosalind Advisors, Inc. ($77,768.30), … WebDec 8, 2024 · NEW YORK, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare...
Is Delcath The Post-Celsion Play On Liver Cancer? - SeekingAlpha
WebApr 6, 2024 · 3 equities research analysts have issued 12 month price objectives for Delcath Systems' shares. Their DCTH share price forecasts range from $14.00 to $19.00. On average, they expect the company's share price to reach $16.67 in the next twelve months. This suggests a possible upside of 195.0% from the stock's current price. WebMar 28, 2024 · Published on March 28, 2024. Delcath Systems, Inc. (Nasdaq: DCTH), a NYC-based interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, signed ... bowlen a12
DCTH Insider Trading Activity Delcath Systems Insider Buys and …
WebOverview. Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) – is designed to administer high-dose chemotherapy to the liver while controlling ... WebFeb 22, 2024 · Since December 2024, medac GmbH, a privately held, multi-national pharmaceutical company based in Germany, has been the licensee for CHEMOSAT in Europe. Delcath and medac are working closely ... WebDCTH Stock Price - Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and … bowle mit rum